Agile Therapeutics Inc. (NASDAQ:AGRX)’s share price was up 3% during mid-day trading on Thursday . The stock traded as high as $7.46 and last traded at $7.46, with a volume of 144,939 shares changing hands. The stock had previously closed at $7.24.

Several equities analysts have recently issued reports on AGRX shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $18.00 target price on shares of Agile Therapeutics in a report on Tuesday, May 10th. Zacks Investment Research upgraded Agile Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Tuesday, May 10th. FBR & Co reiterated a “buy” rating and issued a $17.00 price objective on shares of Agile Therapeutics in a research note on Tuesday, May 10th. Finally, Noble Financial reiterated a “buy” rating and issued a $15.00 price objective on shares of Agile Therapeutics in a research note on Friday, July 8th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Agile Therapeutics has an average rating of “Buy” and a consensus price target of $15.00.

The company’s 50-day moving average is $7.06 and its 200-day moving average is $6.73. The stock’s market cap is $206.15 million.

Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Monday, August 8th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.29). Analysts expect that Agile Therapeutics Inc. will post ($1.26) EPS for the current year.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.